JPRN-jRCT2031220390招募中1 期
Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR Exon 20 Insertion Mutations - BLU-451-1101
Zalutskaya Alena0 个研究点目标入组 15 人开始时间: 2022年10月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •All participants:
- •- Documented EGFR mutation, based on Next-generation sequencing (NGS) testing of tumor or liquid biopsy analyzed in a local Clinical Laboratory Improvement Amendments (CLIA) (or International Organization for Standardization (ISO) 15189)-certified or equivalent laboratory are required. Redacted copies of laboratory results must be available for Sponsor review.
- •- Able to provide a new or archived pretreatment formalin-fixed, paraffin-embedded (FFPE) tumor sample. For participants who received EGFR-targeted therapy subsequent to the most recent archived biopsy, all efforts should be made to obtain a new biopsy unless it is not safe or feasible to obtain one.
- •- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- •- Participants must be without seizures for at least 14 days prior to enrollment, and patients who receive treatment with anti-epileptic drugs must be on stable doses for at least 14 days prior to enrollment.
- •- Adequate hematological, renal, and hepatic function:
- •Participants in Phase 1
- •- Histologically or cytologically confirmed metastatic NSCLC (stage IVA and IVB per American Joint Committee on Cancer (AJCC) 8th edition) or other metastatic cancers except for primary CNS tumors (Part 1A or Part 2 only).
- •- Must have evaluable or measurable disease per RECIST v1.1.
- •- Progression on or after or intolerance to most recent systemic therapy.
- •Participants in Phase 2
- •- Histologically or cytologically confirmed metastatic NSCLC (stage IVA and IVB per AJCC 8th edition).
- •- Must have measurable disease by RECIST 1.1.
- •Other protocol-defined inclusion criteria apply
排除标准
- •- Have disease that is suitable for local therapy administered with curative intent.
- •- Have tumor that harbors known driver alterations (including, but not limited to ROS, BRAF V600E, ALK, RET, HER2, MET, KRAS, NTRK1/2/3, EGFR C797X, or EGFR T790M mutation).
- •- Have NSCLC with mixed cell histology or a tumor with known histologic transformation (NSCLC to SCLC, SCLC to NSCLC, or epithelial to mesenchymal transition).
- •Other protocol-defined exclusion criteria apply
研究者
相似试验
进行中（未招募）
1 期
Phase 1/2 Study of BLU-451 in certain advanced cancersAdvanced cancers with EGFR Exon20 insertions mutationsCTIS2022-502527-21-00Blueprint Medicines Corp.332
终止
1 期
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsLung Neoplasm MalignantCarcinoma, Non-Small-Cell LungRespiratory Tract NeoplasmsNeoplasmsNeoplasms by SiteLung DiseasesRespiratory Tract DiseaseCarcinoma, BronchogenicBronchial NeoplasmsAdenocarcinomaCarcinomaNeoplasms by Histologic TypeEGFR Exon 20 MutationEGFR Exon 20 Insertion MutationEGFR Activating MutationAntineoplastic AgentsMetastatic Lung CancerBrain MetastasesEGFR-mutated NSCLCEGFR Atypical Mutations, Including G719X and L861QNCT05241873Blueprint Medicines Corporation103
尚未招募
Unknown
A phase II study of ABN401 in advanced solid tumors with c-MET gene aberration (Part of KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors [KOSMOS]-II)NeoplasmsKCT0008450Yonsei University Health System, Severance Hospital20
已完成
1 期
A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid TumoursOther Solid TumoursGliomaNCT01792310Laminar Pharmaceuticals54
已完成
1 期
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)NeoplasmsNCT04147234Boehringer Ingelheim42